EPIQ Capital Group

Spotlight Therapeutics is a developer of gene editing therapeutics intended to edit specific cell populations directly in the body. The company's therapeutics are used to create next-generation programmable nucleases that can selectively target and edit cells, enabling physicians to treat their patient in an enhanced way.

Epirus, Inc. specializes in the design and development of advanced artificial intelligence-based defense systems aimed at countering drones and asymmetric technologies. Founded in 2018 and located in Hawthorne, California, the company produces high-powered microwave products, including its flagship technology, ELECTROMAGNETIC PULSE, which serves as a drone countermeasure. This innovative solution employs multiple simultaneous beams to neutralize unmanned aircraft systems, while also utilizing software-defined electromagnetic pulse technology to enhance its effectiveness. By integrating computer vision and machine learning, Epirus aims to optimize the detection and tracking of various threats, providing defense organizations with the capability to stun drones or disrupt swarms effectively. The company's products address critical national security challenges in both defense and commercial sectors.

SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.

VideoAmp is a technology company that offers a comprehensive platform for data-driven advertising, enabling advertisers to optimize their investments across linear TV, OTT, and digital video. The platform provides essential tools for measuring ad performance against relevant business outcomes, utilizing large, high-quality commingled TV datasets and advanced data science methodologies. VideoAmp aims to deliver a privacy-compliant suite of solutions for advertisers, agencies, and publishers to analyze and enhance the full path to conversion. The company measures and optimizes billions in advertising spend annually and has garnered support from several prominent venture capital groups, including The Raine Group and RTL Group.

Windfall Data, Inc. is a San Francisco-based company founded in 2016 that specializes in providing actionable consumer financial data services. The company aims to determine the net worth of households worldwide and serves a diverse range of sectors, including financial services, retail, non-profits, and hospitality. Windfall Data utilizes proprietary algorithms and comprehensive data sets to deliver insights that are refreshed weekly, enabling organizations to effectively identify and engage their most promising constituents. Over 400 organizations leverage Windfall's platform for data-driven marketing, sales, and analytics, enhancing their ability to connect with affluent consumers. The company is supported by various venture capital firms, underscoring its innovative approach to consumer financial data.

Swift Navigation, Inc., founded in 2012 and based in San Francisco, California, specializes in developing precise and affordable global positioning system (GPS) technology. The company is known for its low-cost, high-accuracy real-time kinematics (RTK) receivers, which provide centimeter-level positioning. Its product offerings include the Piksi Multi GNSS Module and the ruggedized Duro Receiver, designed for various applications such as agriculture, robotics, maritime, and industrial use. Additionally, Swift Navigation provides the Skylark cloud corrections service and the Starling GNSS positioning engine, targeting markets like autonomous vehicles and unmanned aerial vehicles. The company has established a reputation for innovation, delivering positioning solutions that significantly outperform traditional GPS accuracy. Swift Navigation's technology supports a wide range of industries, promoting advancements in automation and precision across diverse sectors.

Lineage Logistics is the industry’s leading innovator in temperature-controlled supply chain and logistics. Lineage’s expertise in end-to-end logistical solutions, its unrivaled real estate network, and its use of technology combine to promote food safety, increase distribution efficiency, advance sustainability, lessen environmental impact, and minimize supply chain waste. As a result, Lineage helps customers ranging from Fortune 500 companies to small family-owned businesses increase the efficiency and protect the integrity of their temperature-controlled supply chain. In recognition of the company’s leading innovations, Lineage was recognized as the No 1. Data Science company on Fast Company’s annual list of the World’s Most Innovative Companies in 2019, in addition to ranking 23rd overall in an evaluation of thousands of companies worldwide.

Lucira Health develops a new class of professional and home-health solutions to help illuminate and elucidate health status to expedite decision-making and treatment. The company's at-home test kit is well suited for home use and the molecular nucleic acid amplification technology is adaptable to COVID-19 detection. Lucira Health produces inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world. It enables consumers to take the first step in their healthcare management through at-home diagnosis and a companion mobile app to provide follow up treatment. Lucira Health was founded in 2013 and is headquartered in Emeryville, California, United States.

SpotOn is a payments and software company that aims to transform the merchant services industry by combining payment processing with customer engagement tools. Founded in 2017 and headquartered in San Francisco, California, SpotOn provides a cloud-based platform specifically designed for small and medium-sized businesses. This platform includes a range of comprehensive tools such as payments, point-of-sale systems, custom website creation, appointment scheduling, marketing, customer reviews, analytics, and loyalty programs. By facilitating effective communication and allowing merchants to import existing customer lists, SpotOn enhances business efficiency and empowers merchants to make informed decisions while improving their marketing strategies. The company's commitment to exceptional customer service further supports its mission to help businesses thrive.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company focused on developing oral biologic product candidates aimed at treating autoimmune, inflammatory, metabolic, and other diseases. The company utilizes a proprietary technology platform that enables the active transport of therapeutic agents across the intestinal epithelium, leveraging natural cellular trafficking pathways. Its lead candidate, AMT-101, is an oral gastrointestinal-selective interleukin 10 that has successfully completed a Phase 1b clinical trial for ulcerative colitis and is set to enter Phase 2 trials. Additionally, the company is advancing AMT-126, an oral fusion protein targeting intestinal epithelium barrier function defects. Applied Molecular Transport is dedicated to creating patient-friendly oral formulations, such as tablets and capsules, to enhance treatment accessibility and efficacy. Founded in 2010 and headquartered in South San Francisco, California, the company is building a diverse portfolio of therapeutic modalities, including peptides, proteins, antibodies, and RNA therapeutics.

Lucira Health develops a new class of professional and home-health solutions to help illuminate and elucidate health status to expedite decision-making and treatment. The company's at-home test kit is well suited for home use and the molecular nucleic acid amplification technology is adaptable to COVID-19 detection. Lucira Health produces inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world. It enables consumers to take the first step in their healthcare management through at-home diagnosis and a companion mobile app to provide follow up treatment. Lucira Health was founded in 2013 and is headquartered in Emeryville, California, United States.

Swift Navigation, Inc., founded in 2012 and based in San Francisco, California, specializes in developing precise and affordable global positioning system (GPS) technology. The company is known for its low-cost, high-accuracy real-time kinematics (RTK) receivers, which provide centimeter-level positioning. Its product offerings include the Piksi Multi GNSS Module and the ruggedized Duro Receiver, designed for various applications such as agriculture, robotics, maritime, and industrial use. Additionally, Swift Navigation provides the Skylark cloud corrections service and the Starling GNSS positioning engine, targeting markets like autonomous vehicles and unmanned aerial vehicles. The company has established a reputation for innovation, delivering positioning solutions that significantly outperform traditional GPS accuracy. Swift Navigation's technology supports a wide range of industries, promoting advancements in automation and precision across diverse sectors.

Tenstorrent Inc. is a technology company that develops and manufactures application-specific integrated circuits (ASIC) designed for machine learning and hardware applications. Founded in 2016 and headquartered in Toronto, Canada, with an additional office in Austin, Texas, Tenstorrent's architecture is engineered for use in a range of devices, from battery-powered Internet of Things (IoT) devices to large cloud servers. The company aims to enhance performance and efficiency for artificial intelligence workloads by co-designing hardware, software, and AI algorithms. Its processors are characterized by scalability, programmability, and improved flexibility compared to traditional accelerators like CPUs and GPUs. Tenstorrent's team comprises experts in computer architecture, hardware design, systems engineering, and machine learning, positioning the company to support advancements in technology across various industries.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company focused on developing oral biologic product candidates aimed at treating autoimmune, inflammatory, metabolic, and other diseases. The company utilizes a proprietary technology platform that enables the active transport of therapeutic agents across the intestinal epithelium, leveraging natural cellular trafficking pathways. Its lead candidate, AMT-101, is an oral gastrointestinal-selective interleukin 10 that has successfully completed a Phase 1b clinical trial for ulcerative colitis and is set to enter Phase 2 trials. Additionally, the company is advancing AMT-126, an oral fusion protein targeting intestinal epithelium barrier function defects. Applied Molecular Transport is dedicated to creating patient-friendly oral formulations, such as tablets and capsules, to enhance treatment accessibility and efficacy. Founded in 2010 and headquartered in South San Francisco, California, the company is building a diverse portfolio of therapeutic modalities, including peptides, proteins, antibodies, and RNA therapeutics.

Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.